Trade Carl Zeiss Meditec AG - AFX CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.54 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.019277% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.002946% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | EUR | ||||||||
Margin | 20% | ||||||||
Stock exchange | Germany | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Prev. Close* | 124.88 |
Open* | 125.28 |
1-Year Change* | -16.14% |
Day's Range* | 124.54 - 127.78 |
52 wk Range | 101.75-152.20 |
Average Volume (10 days) | 139.60K |
Average Volume (3 months) | 2.08M |
Market Cap | 11.45B |
P/E Ratio | 37.38 |
Shares Outstanding | 89.44M |
Revenue | 1.96B |
EPS | 3.42 |
Dividend (Yield %) | 0.85938 |
Beta | 0.66 |
Next Earnings Date | May 9, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 31, 2023 | 127.18 | 2.30 | 1.84% | 124.88 | 127.88 | 124.29 |
Mar 30, 2023 | 124.88 | 4.54 | 3.77% | 120.34 | 125.18 | 120.34 |
Mar 29, 2023 | 122.99 | -4.84 | -3.79% | 127.83 | 128.63 | 122.89 |
Mar 28, 2023 | 126.83 | -8.14 | -6.03% | 134.97 | 135.52 | 126.83 |
Mar 27, 2023 | 134.47 | 1.70 | 1.28% | 132.77 | 135.87 | 132.77 |
Mar 24, 2023 | 132.22 | -3.90 | -2.87% | 136.12 | 136.17 | 131.77 |
Mar 23, 2023 | 134.77 | 3.85 | 2.94% | 130.92 | 134.77 | 130.87 |
Mar 22, 2023 | 132.02 | 0.35 | 0.27% | 131.67 | 133.82 | 131.02 |
Mar 21, 2023 | 131.27 | -3.80 | -2.81% | 135.07 | 135.17 | 127.33 |
Mar 20, 2023 | 134.47 | -2.25 | -1.65% | 136.72 | 138.66 | 134.37 |
Mar 17, 2023 | 137.51 | 0.20 | 0.15% | 137.31 | 138.11 | 136.07 |
Mar 16, 2023 | 136.92 | 0.45 | 0.33% | 136.47 | 137.07 | 132.67 |
Mar 15, 2023 | 135.07 | -2.94 | -2.13% | 138.01 | 138.21 | 133.07 |
Mar 14, 2023 | 138.06 | 2.24 | 1.65% | 135.82 | 140.16 | 135.62 |
Mar 13, 2023 | 135.77 | 0.30 | 0.22% | 135.47 | 136.32 | 132.47 |
Mar 10, 2023 | 135.47 | 1.15 | 0.86% | 134.32 | 136.07 | 134.17 |
Mar 9, 2023 | 136.37 | 3.65 | 2.75% | 132.72 | 136.52 | 132.22 |
Mar 8, 2023 | 133.27 | -0.20 | -0.15% | 133.47 | 134.42 | 132.32 |
Mar 7, 2023 | 134.82 | -1.85 | -1.35% | 136.67 | 137.41 | 134.32 |
Mar 6, 2023 | 133.62 | 0.25 | 0.19% | 133.37 | 134.12 | 132.47 |
Carl Zeiss Meditec AG Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 1902.84 | 1646.79 | 1335.45 | 1459.32 | 1280.86 |
Revenue | 1902.84 | 1646.79 | 1335.45 | 1459.32 | 1280.86 |
Cost of Revenue, Total | 775.238 | 679.572 | 589.935 | 627.437 | 570.471 |
Gross Profit | 1127.6 | 967.213 | 745.517 | 831.884 | 710.389 |
Total Operating Expense | 1505.96 | 1273.17 | 1157.9 | 1194.66 | 1083.73 |
Selling/General/Admin. Expenses, Total | 438.06 | 363.98 | 349.161 | 393.913 | 353.646 |
Research & Development | 291.365 | 232.066 | 218.804 | 173.312 | 159.628 |
Operating Income | 396.879 | 373.614 | 177.552 | 264.659 | 197.13 |
Interest Income (Expense), Net Non-Operating | -44.479 | -32.12 | -21.351 | -34.497 | -20.449 |
Other, Net | 51.089 | -2.444 | 22.516 | -0.304 | 2.502 |
Net Income Before Taxes | 403.489 | 339.05 | 178.717 | 229.858 | 179.183 |
Net Income After Taxes | 295.911 | 237.519 | 123.421 | 160.579 | 126.23 |
Minority Interest | -2.002 | -1.243 | -1.036 | -0.823 | 0.233 |
Net Income Before Extra. Items | 293.909 | 236.276 | 122.385 | 159.756 | 126.463 |
Net Income | 293.909 | 236.276 | 122.385 | 159.756 | 126.463 |
Income Available to Common Excl. Extra. Items | 293.909 | 236.276 | 122.385 | 159.756 | 126.463 |
Income Available to Common Incl. Extra. Items | 293.909 | 236.276 | 122.385 | 159.756 | 126.463 |
Diluted Net Income | 293.909 | 236.276 | 122.385 | 159.756 | 126.463 |
Diluted Weighted Average Shares | 89.4406 | 89.4406 | 89.4406 | 89.4406 | 89.4406 |
Diluted EPS Excluding Extraordinary Items | 3.28608 | 2.64171 | 1.36834 | 1.78617 | 1.41393 |
Dividends per Share - Common Stock Primary Issue | 1.1 | 0.9 | 0.5 | 0.65 | 0.55 |
Diluted Normalized EPS | 3.28608 | 2.62254 | 1.41621 | 1.826 | 1.44229 |
Unusual Expense (Income) | -2.447 | 0 | |||
Other Operating Expenses, Total | 1.294 | 0 | -0.015 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Total revenue | 470.3 | 569.936 | 477.495 | 445.229 | 410.176 |
Revenue | 470.3 | 569.936 | 477.495 | 445.229 | 410.176 |
Cost of Revenue, Total | 212.9 | 227.538 | 193.645 | 176.654 | 177.401 |
Gross Profit | 257.4 | 342.398 | 283.85 | 268.575 | 232.775 |
Total Operating Expense | 410 | 448.957 | 378.919 | 342.273 | 335.808 |
Selling/General/Admin. Expenses, Total | 116.1 | 133.26 | 111.092 | 95.837 | 97.871 |
Research & Development | 81 | 87.165 | 73.972 | 69.692 | 60.536 |
Unusual Expense (Income) | |||||
Operating Income | 60.3 | 120.979 | 98.576 | 102.956 | 74.368 |
Interest Income (Expense), Net Non-Operating | 11.7 | -2.679 | -12.957 | -8.662 | -20.181 |
Other, Net | 1 | 22.689 | 2.71 | 25.805 | -0.115 |
Net Income Before Taxes | 73 | 140.989 | 88.329 | 120.099 | 54.072 |
Net Income After Taxes | 50.5 | 103.811 | 61.996 | 92.095 | 38.009 |
Minority Interest | 0.5 | -1.102 | 0.536 | -1.367 | -0.069 |
Net Income Before Extra. Items | 51 | 102.709 | 62.532 | 90.728 | 37.94 |
Net Income | 51 | 102.709 | 62.532 | 90.728 | 37.94 |
Income Available to Common Excl. Extra. Items | 51 | 102.709 | 62.532 | 90.728 | 37.94 |
Income Available to Common Incl. Extra. Items | 51 | 102.709 | 62.532 | 90.728 | 37.94 |
Diluted Net Income | 51 | 102.709 | 62.532 | 90.728 | 37.94 |
Diluted Weighted Average Shares | 89.4737 | 89.7249 | 89.3318 | 89.8297 | 89.5912 |
Diluted EPS Excluding Extraordinary Items | 0.57 | 1.14471 | 0.7 | 1.01 | 0.42348 |
Dividends per Share - Common Stock Primary Issue | 0 | 1.1 | 0 | 0 | 0 |
Diluted Normalized EPS | 0.59165 | 1.14471 | 0.7 | 1.01 | 0.42348 |
Other Operating Expenses, Total | 0 | 0.994 | 0.21 | 0.09 | 0 |
Total Adjustments to Net Income | 0 |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total Current Assets | 1604.02 | 1290.51 | 1304.33 | 1251.06 | 1207.89 |
Cash and Short Term Investments | 7.439 | 6.202 | 22.639 | 7.843 | 8.315 |
Cash | 7.439 | 6.202 | 22.639 | 6.678 | 3.925 |
Cash & Equivalents | |||||
Total Receivables, Net | 1294.65 | 979.93 | 1000.34 | 981.046 | 935.904 |
Accounts Receivable - Trade, Net | 185.94 | 165.158 | 205.789 | 192.33 | 195.256 |
Total Inventory | 286.375 | 286.36 | 268.322 | 248.092 | 234.303 |
Prepaid Expenses | 9.502 | 8.144 | 10.759 | 9.352 | 9.986 |
Other Current Assets, Total | 6.049 | 9.871 | 2.266 | 4.723 | 19.38 |
Total Assets | 2395.97 | 2014.85 | 2022.13 | 1662.05 | 1623.11 |
Property/Plant/Equipment, Total - Net | 199.555 | 135.265 | 116.752 | 62.632 | 58.696 |
Property/Plant/Equipment, Total - Gross | 379.88 | 320.308 | 280.47 | 196.305 | 174.346 |
Accumulated Depreciation, Total | -180.325 | -185.043 | -163.718 | -133.673 | -115.65 |
Goodwill, Net | 328.714 | 326.51 | 338.094 | 185.638 | 174.313 |
Intangibles, Net | 153.698 | 145.221 | 144.336 | 74.087 | 68.491 |
Long Term Investments | 6.713 | 4.108 | 5.173 | 0.122 | 19.3 |
Note Receivable - Long Term | 9.191 | 9.225 | 10.961 | 9.29 | 14.565 |
Other Long Term Assets, Total | 94.079 | 104.014 | 102.484 | 79.227 | 79.855 |
Total Current Liabilities | 448.118 | 297.584 | 339.6 | 280.18 | 316.078 |
Accounts Payable | 145.465 | 91.679 | 118.12 | 101.437 | 100.463 |
Accrued Expenses | 137.816 | 109.294 | 115.657 | 98.181 | 80.259 |
Notes Payable/Short Term Debt | 0.645 | 0.209 | 0.192 | 15.71 | 5.733 |
Current Port. of LT Debt/Capital Leases | 19.341 | 15.512 | 14.661 | 3.529 | 2.819 |
Other Current Liabilities, Total | 144.851 | 80.89 | 90.97 | 61.323 | 126.804 |
Total Liabilities | 736.641 | 583.133 | 623.69 | 368.588 | 407.731 |
Total Long Term Debt | 178.425 | 140.636 | 151.837 | 7.321 | 3.588 |
Long Term Debt | 76.496 | 87.543 | 109.009 | 0 | 0.593 |
Capital Lease Obligations | 101.929 | 53.093 | 42.828 | 7.321 | 2.995 |
Deferred Income Tax | 15.438 | 17.166 | 18.198 | 5.234 | 8.918 |
Minority Interest | 18.056 | 18.841 | 18.517 | 21.17 | 26.358 |
Other Liabilities, Total | 76.604 | 108.906 | 95.538 | 54.683 | 52.789 |
Total Equity | 1659.33 | 1431.72 | 1398.44 | 1293.46 | 1215.38 |
Common Stock | 89.441 | 89.441 | 89.441 | 89.441 | 89.441 |
Additional Paid-In Capital | 620.137 | 620.137 | 620.137 | 620.137 | 620.137 |
Retained Earnings (Accumulated Deficit) | 1000.48 | 808.922 | 744.673 | 632.486 | 555.215 |
Other Equity, Total | -50.729 | -86.783 | -55.812 | -48.6 | -49.416 |
Total Liabilities & Shareholders’ Equity | 2395.97 | 2014.85 | 2022.13 | 1662.05 | 1623.11 |
Total Common Shares Outstanding | 89.4406 | 89.4406 | 89.4406 | 89.4406 | 89.4406 |
Short Term Investments | 0 | 1.165 | 4.39 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total Current Assets | 1674.57 | 1604.02 | 1451.74 | ||
Cash and Short Term Investments | 21.589 | 17.918 | 17.352 | ||
Cash & Equivalents | 8.401 | 7.439 | 8.315 | ||
Short Term Investments | 13.188 | 10.479 | 9.037 | ||
Total Receivables, Net | 1298.01 | 1274.3 | 1140.1 | ||
Accounts Receivable - Trade, Net | 156.475 | 185.94 | 164.928 | ||
Total Inventory | 328.867 | 286.375 | 274.078 | ||
Other Current Assets, Total | 26.105 | 25.422 | 20.211 | ||
Total Assets | 2526.01 | 2395.97 | 2217.7 | ||
Property/Plant/Equipment, Total - Net | 205.703 | 199.555 | 189.302 | ||
Goodwill, Net | 379.934 | 328.714 | 323.349 | ||
Intangibles, Net | 163.484 | 153.698 | 144.045 | ||
Long Term Investments | 6.843 | 6.713 | 4.843 | ||
Note Receivable - Long Term | 9.096 | 9.191 | 8.339 | ||
Other Long Term Assets, Total | 86.374 | 94.079 | 96.077 | ||
Total Current Liabilities | 499.258 | 448.118 | 347.866 | ||
Accounts Payable | 140.474 | 145.465 | 123.336 | ||
Accrued Expenses | 109.277 | 127.787 | 92.307 | ||
Notes Payable/Short Term Debt | 0 | 0 | 0 | ||
Current Port. of LT Debt/Capital Leases | 18.97 | 19.341 | 17.876 | ||
Other Current Liabilities, Total | 230.537 | 155.525 | 114.347 | ||
Total Liabilities | 788.612 | 736.641 | 672.152 | ||
Total Long Term Debt | 189.666 | 178.425 | 192.216 | ||
Long Term Debt | 88.588 | 76.496 | 90.194 | ||
Capital Lease Obligations | 101.078 | 101.929 | 102.022 | ||
Deferred Income Tax | 15.035 | 15.438 | 16.932 | ||
Minority Interest | 18.693 | 18.056 | 17.705 | ||
Other Liabilities, Total | 65.96 | 76.604 | 97.433 | ||
Total Equity | 1737.39 | 1659.33 | 1545.55 | ||
Common Stock | 89.441 | 89.441 | 89.441 | ||
Additional Paid-In Capital | 620.137 | 620.137 | 620.137 | ||
Retained Earnings (Accumulated Deficit) | 1048.65 | 1000.48 | 909.534 | ||
Other Equity, Total | -20.833 | -50.729 | -73.565 | ||
Total Liabilities & Shareholders’ Equity | 2526.01 | 2395.97 | 2217.7 | ||
Total Common Shares Outstanding | 89.4406 | 89.4406 | 89.4406 |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Net income/Starting Line | 237.519 | 123.421 | 160.579 | 126.23 | 135.778 |
Cash From Operating Activities | 362.663 | 178.527 | 219.634 | 187.207 | 37.732 |
Cash From Operating Activities | 61.584 | 60.425 | 48.37 | 31.282 | 24.235 |
Non-Cash Items | 110.074 | 58.691 | 76.373 | 54.526 | 47.269 |
Cash Taxes Paid | 97.908 | 58.964 | 65.07 | 48.364 | 54.73 |
Cash Interest Paid | 1.629 | 1.365 | 1.903 | 1.94 | 1.559 |
Changes in Working Capital | -46.514 | -64.01 | -65.688 | -24.831 | -169.55 |
Cash From Investing Activities | -75.2 | -70.947 | -145.846 | -28.874 | -55.931 |
Capital Expenditures | -66.101 | -44.986 | -46.711 | -34.756 | -39.022 |
Other Investing Cash Flow Items, Total | -9.099 | -25.961 | -99.135 | 5.882 | -16.909 |
Cash From Financing Activities | -285.889 | -122.961 | -58.637 | -157.237 | 14.494 |
Financing Cash Flow Items | -223.862 | -48.775 | 4.321 | -104.529 | -259.854 |
Total Cash Dividends Paid | -44.72 | -58.136 | -49.192 | -49.192 | -37.565 |
Issuance (Retirement) of Debt, Net | -17.307 | -16.05 | -13.766 | -3.516 | -3.123 |
Foreign Exchange Effects | -0.337 | -1.056 | 0.81 | 1.657 | -1.08 |
Net Change in Cash | 1.237 | -16.437 | 15.961 | 2.753 | -4.785 |
Issuance (Retirement) of Stock, Net | 0 | 315.036 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | 130.104 | 101.501 | |||
Cash From Operating Activities | 74.484 | 151.878 | |||
Cash From Operating Activities | 33.045 | 29.924 | |||
Non-Cash Items | 16.671 | 44.673 | |||
Cash Taxes Paid | 61.722 | 41.015 | |||
Cash Interest Paid | 0.679 | 0.67 | |||
Changes in Working Capital | -105.336 | -24.22 | |||
Cash From Investing Activities | -54.311 | -28.769 | |||
Capital Expenditures | -35.335 | -23.26 | |||
Other Investing Cash Flow Items, Total | -18.976 | -5.509 | |||
Cash From Financing Activities | -18.33 | -124.663 | |||
Financing Cash Flow Items | -9.441 | -116.396 | |||
Issuance (Retirement) of Debt, Net | -8.889 | -8.267 | |||
Foreign Exchange Effects | -0.881 | -0.31 | |||
Net Change in Cash | 0.962 | 2.113 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Carl Zeiss Group | Corporation | 59.14 | 52895153 | 35776 | 2022-11-15 | |
Capital Research Global Investors | Investment Advisor | 4.9912 | 4464153 | -46868 | 2023-02-13 | LOW |
Capital World Investors | Investment Advisor | 1.6403 | 1467117 | 0 | 2023-01-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 1.1483 | 1027089 | 1286 | 2023-02-28 | LOW |
Invesco Advisers, Inc. | Investment Advisor | 0.8941 | 799668 | -11471 | 2023-01-31 | LOW |
Groupama Asset Management | Investment Advisor | 0.8665 | 775034 | -37628 | 2022-09-30 | LOW |
DWS Investment GmbH | Investment Advisor/Hedge Fund | 0.7616 | 681161 | 27 | 2023-02-28 | LOW |
BlackRock Asset Management Deutschland AG | Investment Advisor | 0.7572 | 677231 | -8165 | 2023-02-28 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.7343 | 656754 | -13903 | 2023-02-28 | LOW |
Allianz Global Investors GmbH | Investment Advisor | 0.6845 | 612201 | -1744 | 2023-02-28 | LOW |
Amundi Asset Management, SAS | Investment Advisor/Hedge Fund | 0.5952 | 532334 | 153016 | 2023-02-28 | HIGH |
Candriam Luxembourg S.A. | Investment Advisor | 0.5894 | 527175 | -10543 | 2023-01-31 | HIGH |
La Financière de l'Echiquier | Investment Advisor | 0.5405 | 483394 | -6 | 2022-11-30 | LOW |
Oddo BHF Asset Management S.A.S | Investment Advisor/Hedge Fund | 0.4626 | 413722 | -16606 | 2023-01-31 | LOW |
BlackRock Advisors (UK) Limited | Investment Advisor/Hedge Fund | 0.442 | 395285 | 17110 | 2023-02-28 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 0.4095 | 366292 | -451602 | 2022-12-31 | LOW |
Deka Investment GmbH | Investment Advisor/Hedge Fund | 0.332 | 296921 | -10699 | 2023-02-28 | LOW |
Credit Mutuel Asset Management | Investment Advisor | 0.2971 | 265728 | 250534 | 2022-12-31 | HIGH |
Columbia Threadneedle Investments (UK) | Investment Advisor/Hedge Fund | 0.2487 | 222410 | -1214 | 2022-11-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.2357 | 210844 | 1186 | 2023-01-31 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Carl Zeiss Meditec Company profile
About Carl Zeiss Meditec AG
Carl Zeiss Meditec AG is a Germany-based medical technology and device company. It offers offers complete solutions to diagnose and treat ophtalmic diseases, visualization solutions for microsurgery and other technologies, such as intraoperative radiotherapy. The Company operates in two segments: Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment comprises activities in the area of ophthalmology, such as intraocular lenses, surgical visualization solutions and medical laser and diagnostic systems. The Microsurgery segment includes activities of neuro, ear, nose and throat surgery, as well as the activities in the field of intraoperative radiation. The Company has various production sites in Europe, the United States and Asia.
Financial summary
BRIEF: For the three months ended 31 December 2021, Carl Zeiss Meditec AG revenues increased 11% to EUR410.2M. Net income decreased 18% to EUR37.9M. Revenues reflect Ophthalmic Devices segment increase of 10% to EUR310.9M, Microsurgery segment increase of 16% to EUR99.3M, Asia/Pacific Region segment increase of 15% to EUR181.5M, EMEA segment increase of 5% to EUR114.1M.
Equity composition
10/2006, Rights Issue, 3 new shares for every 2 shares held @ EUR 10.1 (Factor: 1.369066).
Industry: | Advanced Medical Equipment & Technology (NEC) |
Göschwitzer Straße 51-52
JENA
THUERINGEN 07745
DE
Income Statement
- Annual
- Quarterly
News

PRECIOUS-Fed slowdown bets steer gold toward second quarterly rise
Gold prices slipped on Friday, but the safe-haven metal was bound for its second straight quarterly rise after recent banking turmoil raised hopes of a less-aggressive U.S. Federal Reserve and shored up interest in bullion.
09:37, 31 March 2023
Singapore's DBS has seen inflows in SVB aftermath, CEO says
DBS Group, Singapore's largest bank, has benefited from inflows amounting to a "few hundred millions" in the aftermath of the collapse of Silicon Valley Bank, its chief executive said on Friday.
09:24, 31 March 2023
US STOCKS-Futures muted as investors await key inflation data
U.S. stock index futures were flat on Friday as investors steered clear of big bets ahead of crucial inflation data, amid receding fears of a banking crisis.
09:16, 31 March 2023
Asia M&As drop to decade low as tumultuous backdrop deters dealmaking
Mergers and acquisitions (M&A) in the Asia-Pacific region fell to a decade low in the first three months of this year as a tumultuous geopolitical and macroeconomic environment left dealmakers cautious.
09:14, 31 March 2023
Coal India surpasses annual output target for first time in 17 years
Coal India Ltd said on Friday it had breached its annual production target of 700 million tonnes, the first time it had surpassed its goal since the fiscal year that ended in March 2006.
09:13, 31 March 2023
Global IPOs marred by banks and recession enjoy few bright spots
A banking crisis and worries of a recession have dampened the outlook for initial public offerings (IPOs) this year, prompting companies to slow down their plans to go public in what is likely to result in lower fees for investment banks.
09:06, 31 March 2023
UniCredit shareholders gather to vote on CEO's new pay scheme
Shareholders in UniCredit met on Friday to vote on a new pay scheme for Chief Executive Andrea Orcel designed to reward outperformance with a 30% pay raise.
09:04, 31 March 2023People also watch
Still looking for a broker you can trust?
Join the 500.000+ traders worldwide that chose to trade with Capital.com